Drugs /

rociletinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor CO-1686 binds to and inhibits mutant forms of EGFR, including T790M, thereby leading to cell death of resistant tumor cells. Compared to other EGFR inhibitors, CO-1686 inhibits T790M, a secondary acquired resistance mutation, as well as other mutant EGFRs and may have therapeutic benefits in tumors with T790M-mediated resistance to other EGFR tyrosine kinase inhibitors. This agent shows minimal activity against wild-type EGFR, hence does not cause certain dose-limiting toxicities.

Clinical Trials

View Clinical Trials for rociletinib

Rociletinib has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating rociletinib, 1 is phase 2 (0 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for rociletinib clinical trials.

Non-small cell lung carcinoma is the most common disease being investigated in rociletinib clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Rociletinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rociletinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
co-1686, rociletinib, egfr inhibitor co-1686
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
EGFR
NCIT ID [1]:
C99905

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.